J.P. Morgan maintains an 'Overweight' rating on Acorda Therapeutics (Nasdaq: ACOR), adds stock to Focus List ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE